Avara Management Ltd is Director & 10% Owner at Royalty Pharma plc (RPRX). They have made 6 open-market trades across 1 company since 2022, most recently 2023-12-29.
CIK 0001814934
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RPRX | 2,477,520 | $151.1M |
Shares reported on the most recent Form 4, priced at the 2024-01-03 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 33% | 33% | 67% |
| Avg Move | -0.7% | -0.4% | -1.8% |
| Scored | 6 | 6 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RPRX | SELL | 2023-12-29 | 2024-01-03 | $28.04 | $3.7M | +2.4% | +1.3% | +6.1% |
| RPRX | SELL | 2023-12-13 | 2023-12-15 | $28.93 | $38.9M | +1.9% | +3.5% | +8.7% |
| RPRX | SELL | 2022-12-05 | 2022-12-07 | $43.15 | $7.3M | -5.9% | -9.4% | -18.2% |
| RPRX | SELL | 2022-09-28 | 2022-09-30 | $41.05 | $2.7M | +1.9% | +5.0% | -1.9% |
| RPRX | SELL | 2022-09-22 | 2022-09-26 | $41.17 | $17.4M | +2.2% | +4.6% | -2.4% |
| RPRX | SELL | 2022-09-07 | 2022-09-09 | $42.70 | $42.7M | -6.8% | -7.5% | -3.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.